Efficacy and applications for PuraStat® use in the management of unselected gastrointestinal bleeding: A retrospective observational study

Table 1 General demographic, biochemical and endoscopic data, n = 45, n (%)

Variable	Value
Demographic data
Age (mean ± SD)	65.8 ± 13.2
Gender	Female 17 (37.8)/male 28 (62.2)
Antiplatelet (aspirin 4, aspirin + clopidogrel 1, clopidogrel 1, prasugel 1)	7 (15.6)
Anticoagulant (DOAC 8, Warfarin 2, Heparin 1)	12 (26.7)
PPI	27 (60)
Charlson index score
0	7 (15.6)
1-2	11 (24.4)
3-4	18 (40)
≥ 5	9 (20)
Transfusion	26 (57.8)
Type of episode
First episode	31 (68.9)
Re-bleeding	13 (28.9)
Second look	1 (2.2)
Biological data (mean ± SD)
BP initial	113 ± 24.4
BP lower 24 hours	107 ± 23.1
HR initial	91.7 ± 21.7
HR higher 24 hours	95.9 ± 21.3
Hb initial	9.2 ± 2.6
Hb lower 24 hours	8.3 ± 2.6
Endoscopic data
Type of procedures
Gastroscopy	35 (77.7)
Colonoscopy	7 (15.5)
ERCP	2 (4.4)
Enteroscopy	1 (2.2)
Type of lesions
Peptic ulcer	15 (33.3)
Postpolypectomy bleeding	8 (17.8)
Neoplasia	6 (13.3)
Peptic oesophagitis	5 (11.1)
Post-sphincterotomy	2 (4.4)
Others	9 (20)

ERCP: Endoscopic retrograde cholangiopancreatography; BP: Blood pressure; HR: Heart rate; Hb: Haemoglobin; DOAC: Direct oral anti coagulant.